<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tetrabenazine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB04844</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington&#8217;s disease. <span class="caps">FDA</span> approved on August 15, 2008.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB04844/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB04844/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04844.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04844.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04844.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04844.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04844.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB04844">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>TBZ</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tetra benazin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tetrabenazina</td><td>Spanish</td><td>INN</td></tr><tr><td>Tetrabenazinum</td><td>Latin</td><td>INN</td></tr><tr><td>Tetrabenzaine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tetrabenzine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Nitoman</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rubigen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Xenazine</td><td>Prestwick Pharmaceuticals Inc. </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/adrenergic-uptake-inhibitors">Adrenergic Uptake Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>58-46-8</td></tr><tr><th>Weight</th><td>Average: 317.4226<br>Monoisotopic: 317.199093735</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>27</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>MKJIEFSOBYUXJB-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Isoquinolines and Derivatives</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Isoquinolines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Anisoles; Alkyl Aryl Ethers; Piperidinones; Ketones; Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; alkyl aryl ether; piperidinone; benzene; piperidine; ketone; tertiary amine; polyamine; ether; carbonyl group; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the isoquinolines and derivatives. These are aromatic polycyclic compounds containing an isoquinoline moiety, which consists of a benzene ring fused to a pyridine ring and forming benzo[c]pyridine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia </td></tr><tr><th>Pharmacodynamics</th><td>Prolongation of the QTc interval has been observed at doses of 50 mg. In rats, it has been observed that tetrabenazine or its metabolites bind to melanin-containing tissues such as the eyes and skin. After a single oral dose of radiolabeled tetrabenazine, radioactivity was still detected in eye and fur at 21 days post dosing. </td></tr><tr><th>Mechanism of action</th><td>Tetrabenazine is a reversible human vesicular monoamine transporter type 2 inhibitor (Ki = 100 nM). It acts within the basal ganglia and promotes depletion of monoamine neurotransmitters serotonin, norepinephrine, and dopamine from stores. It also decreases uptake into synaptic vesicles. Dopamine is required for fine motor movement, so the inhibition of its transmission is efficacious for hyperkinetic movement. Tetrabenazine exhibits weak in vitro binding affinity at the dopamine D2 receptor (Ki = 2100 nM).</td></tr><tr><th>Absorption</th><td>Following oral administration of tetrabenazine, the extent of absorption is at least 75%.  After single oral doses ranging from 12.5 to 50 mg, plasma concentrations of tetrabenazine are generally below the limit of detection because of the rapid and extensive hepatic metabolism of tetrabenazine. Food does not affect the absorption of tetrabenazine. 
Cmax, oral = 4.8 ng/mL in HD or tardive dyskinesia patients;  
Tmax, oral = 69 min in HD or tardive dyskinesia patients</td></tr><tr><th>Volume of distribution</th><td><p>Steady State, IV, in HD or tardive dyskinesia patients: 385L. <br>
Tetrabenazine is rapidly distributed to the brain following IV injection. The site with the highest binding is the striatum, while the lowest binding was observed in the cortex.</p></td></tr><tr><th>Protein binding</th><td>Tetrabenazine = 82 - 88%;
&#945;-HTBZ = 60 - 68%;
&#946;-HTBZ = 59 - 63%.   </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Tetrabenazine is hepatically metabolized. Carbonyl reductase in the liver is responsible for the formation of two major active metabolites: &#945;-dihydrotetrabenazine (&#945;-HTBZ) and &#946;-dihydrotetrabenazine (&#946;-HTBZ). &#945;-HTBZ is further metabolized into 9-desmethyl-&#945;-DHTBZ, a minor metabolite by CYP2D6 and with some contribution of CYP1A2. &#946;-HTBZ is metabolized to another major circulating metabolite, 9-desmethyl-&#946;-DHTBZ, by CYP2D6. The Tmax of this metabolite is 2 hours post-administration of tetrabenazine.  </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tetrabenazine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00458">alpha-dihydrotetrabenazine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/467">Details</a></td></tr><tr><td>Tetrabenazine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00800">b-dihydrotetrabenazine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/821">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>After oral administration, tetrabenazine is extensively hepatically metabolized, and the metabolites are primarily renally eliminated (75%). Tetrabenazine is also cleared fecally (7% to 16%). Unchanged tetrabenazine has not been found in human urine. Urinary excretion of &#945;-HTBZ or &#946;-HTBZ (the major metabolites) accounted for less than 10% of the administered dose.</td></tr><tr><th>Half life</th><td>&#945;-HTBZ = 7 hours; 
&#946;-HTBZ = 5 hours;
9-desmethyl-&#946;-DHTBZ = 12 hours. </td></tr><tr><th>Clearance</th><td><p>IV, 1.67 L/min in HD or tardive dyskinesia patients</p></td></tr><tr><th>Toxicity</th><td>Dose-limiting adverse effects are sedation, parkinsonism, akathsia, and depression.
LD50 oral, mouse: 550 mg/kg </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.995</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9639</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8608</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7819</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8908</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.7631</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6484</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8444</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.6448</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.8091</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7482</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9042</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7084</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8191</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8308</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8718</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6674
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9083
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9974
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.8540 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6451
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7524
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Biovail americas corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Laboratories Fournier Sca</li>
<li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>12.5 mg, 25 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01063">Acetophenazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB01238">Aripiprazole</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB00907">Cocaine</a></td><td>CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Patients receiving a strong inhibitor of CYP2D6 together with tetrabenazine should not exceed 50mg of tetrabenazine. Also, patients already taking tetrabenazine prior to starting a strong CYP2D6 inhibitor should have their tetrabenazine dose reduced by 50% upon initiation of the strong CYP2D6 inhibitor.</td></tr><tr><td><a href="/drugs/DB00450">Droperidol</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose. </td></tr><tr><td><a href="/drugs/DB00875">Flupentixol</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB00623">Fluphenazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB00614">Furazolidone</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Furazolidine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Isocarboxazid. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01235">L-DOPA</a></td><td>Tetrabenazine may cause Parkinsonian symptoms and neutralize the effect of Levodopa.</td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Linezolid. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Inhibit biochemical and behavioural effects of tetrabenazine. Heed caution when using agents in combination. </td></tr><tr><td><a href="/drugs/DB00408">Loxapine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB01233">Metoclopramide</a></td><td>Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Moclobemide. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01618">Molindone</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB00334">Olanzapine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB01267">Paliperidone</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Paroxetine is a strong CYP2D6 inhibitor thus increasing half life of dihydrotetrabenazine moieties. Dose of tetrabenazine should be reduced </td></tr><tr><td><a href="/drugs/DB00850">Perphenazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Phenelzine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB01168">Procarbazine</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Procarbazine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00433">Prochlorperazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose. </td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Rasagiline. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00206">Reserpine</a></td><td>Reserpine may increase the adverse/toxic effects of tetrabenazine as they have similar pharmacologic properties. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00734">Risperidone</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Selegiline. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may increase the QTc-prolonging effect of Tetrabenazine. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Tetrabenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tetrabenazine if Terbinafine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Tetrabenazine may increase the adverse/toxic effects of Tranylcypromine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00831">Trifluoperazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Tetrabenazine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>